Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?

Core Viewpoint - Astria Therapeutics, Inc. (ATXS) has seen an 8.3% increase in share price over the past four weeks, closing at $6.76, with a potential upside of 333.9% based on Wall Street analysts' mean price target of $29.33 [1] Price Targets - The average price target consists of nine estimates ranging from a low of $16.00 to a high of $49.00, with a standard deviation of $9.19, indicating variability among analysts [2] - The lowest estimate suggests a 136.7% increase from the current price, while the highest estimate indicates a potential upside of 624.9% [2] Analyst Consensus and Earnings Estimates - Analysts are optimistic about ATXS's earnings prospects, as indicated by a trend of upward revisions in earnings estimates, which historically correlates with stock price movements [11] - Over the last 30 days, five earnings estimates have been revised upward, leading to a 10.1% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank - ATXS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [13] Conclusion on Price Targets - While the consensus price target may not be a reliable measure of the extent of potential gains, it does provide a directional guide for price movement [14]